SG plus pembrolizumab and carboplatin had activity in mNSCLC. When combined with pembrolizumab and carboplatin, SG was tolerated at a dose of 7.5 mg/kg.

3 days ago

Journal

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab) • carboplatin • Trodelvy (sacituzumab govitecan-hziy)

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=218, Completed, Sandoz | Suspended --> Completed

5 days ago

Trial completion

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK rearrangement

Keytruda (pembrolizumab) • cisplatin • carboplatin

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study (clinicaltrials.gov)

P2, N=35, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.

6 days ago

New P2 trial

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M

JS111

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=1410, Recruiting, Pfizer | N=387 --> 1410

6 days ago

Enrollment change • Trial initiation date

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab)

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (clinicaltrials.gov)

P=N/A, N=140, Completed, AstraZeneca | Recruiting --> Completed | N=105 --> 140

6 days ago

Trial completion • Enrollment change

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)

MSI-H/dMMR • BRAF mutation • HER-2 expression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type

Enhertu (fam-trastuzumab deruxtecan-nxki)

20230127: A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy (2023-508359-38-00)

P2/3, N=84, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting

6 days ago

Enrollment closed

Keytruda (pembrolizumab)

POD1UM-304: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=583, Completed, Incyte Corporation | Active, not recruiting --> Completed

6 days ago

Trial completion

cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Zynyz (retifanlimab-dlwr)

ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P1/2, N=56, Recruiting, AstraZeneca | N=43 --> 56

6 days ago

Enrollment change

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)

PIPSeN: Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=180, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=600 --> 180 | Unknown status --> Terminated; study design, change of standard of care, enrollment difficulties

8 days ago

Enrollment change • Trial termination • Platinum sensitive

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

ALK translocation

Lynparza (olaparib)

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (clinicaltrials.gov)

P3, N=220, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

8 days ago

Enrollment open

Avastin (bevacizumab)